Skip to main content
. 2021 Mar 19;7:GO.20.00572. doi: 10.1200/GO.20.00572

FIG 3.

FIG 3

The trend of regimens prescribed as a first-line treatment between 2012 and 2019. MP, melphalan/prednisolone; RD, lenalidomide/dexamethasone; TD, thalidomide/dexamethasone; TMP, thalidomide/melphalan/prednisolone; VCD, bortezomib/cyclophosphamide/dexamethasone; VD, bortezomib/dexamethasone; VMP, bortezomib/melphalan/prednisolone; VRD, bortezomib/lenalidomide/dexamethasone; VTD, bortezomib/thalidomide/dexamethasone.